Prenetics Global Reports Q1 Loss of $1.36 Per Share
PRE has more than doubled off its 52-week low of $6.88.
Summary
Prenetics Global reported a first-quarter loss of $1.36 per share. This final loss per share figure follows the preliminary Q1 2026 results announced on May 14th, which highlighted strong revenue growth for its IM8 brand and raised full-year guidance, alongside an operating loss. The reported loss confirms the company is still unprofitable as it executes its strategic shift to consumer health.
At the time of this announcement, PRE was trading at $20.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $352.2M. The 52-week trading range was $6.88 to $23.63. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.